Litcius/Paper detail

CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

Sam Z. Thalji, Mandana Kamgar, Ben George, Mohammed Aldakkak, Kathleen K. Christians, Callisia N. Clarke, Bradley A. Erickson, William A. Hall, Parag Tolat, Zachary L. Smith, Douglas B. Evans, Susan Tsai

2023Annals of Surgical Oncology14 citationsDOI

Topics & Concepts

FOLFIRINOXMedicineGemcitabineChemotherapyPancreatic cancerInternal medicineCA19-9Neoadjuvant therapyIrinotecanGastroenterologyOncologyCancerSurgeryColorectal cancerBreast cancerPancreatic and Hepatic Oncology ResearchCancer Research and TreatmentsPancreatitis Pathology and Treatment
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer | Litcius